ロード中...
Targeting Protein Prenylation in Progeria
A clinical trial of a protein farnesyltransferase inhibitor (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) was recently completed. Here, we discuss the mutation that causes HGPS, the rationale for inhibiting protein farnesyltransferase, the potential limitations of thi...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3725554/ https://ncbi.nlm.nih.gov/pubmed/23390246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3005229 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|